Before you blindly accept another product from Pfizer, take a few moments to learn about this company.
- Recently, a government commissioned report showed that both the Moderna and Pfizer COVID gene therapy shots cause myocarditis.
- Pfizer has been found guilty and confessed to misleading the public on the COVID shot.
- Demonstrating clear conflicts of interest, the DOJ asked the court to toss a whistleblower lawsuit alleging Pfizer defrauded the U.S. government, which Pfizer also attempted to wiggle out of because it said the government was aware of the fraud.
- Pfizer stands accused of falsifying data, blind trial failures, and awareness that at least one exec was aware that members of the company’s staff were ‘falsifying data.’
- This is not the first time Pfizer has been guilty. It paid $2.3 BILLION in a 2009 settlement for safety violations, false medical claims, corruption, and bribery – the largest healthcare fraud settlement in the history of the U.S. DOJ.
- Pfizer has to settle more than 10,000 lawsuits about cancer risks related to the now-discontinued heartburn drug Zantac. NDMA was found in drug samples.
- Pfizer has been fined heavily in the past due to violating the law over an extensive period of time.
- In an unprecedented move, Pfizer is developing a direct-to-consumer platform to sell some of its drugs online, bypassing primary care physicians.
- Pfizer has also paid the largest civil fraud settlement of $1 BILLION.
- Another Pfizer whistleblower confirms the COVID shot is a bioweapon.
- Scientists globally are concerned about the DNA contamination issue in the Pfizer shot.
- Pfizer collaborated with German biotech company BioNTech for the COVID gene therapy injection, a company that had only ever previously done trials for cancer therapies, none of which ever made it to a large-scale phase 3 clinical trial and one of which prematurely ended for unknown reasons. A new preprint by Rubio-Casillas et al. in the International Journal of Biological Macromolecules asks ‘N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?‘ Turns out it is a friend of cancer. Further, “substituting N1-methyl-pseudouridine for naturally occurring uridine is precisely the innovation at the heart of BioNTech’s mRNA platform, which is thus, in reality, a modRNA or modified RNA platform.” In short, “adding 100 % of N1-methyl-pseudouridine (m1Ψ) to the mRNA vaccine in a melanoma model stimulated cancer growth and metastasis, while non-modified mRNA vaccines induced opposite results, thus suggesting that COVID-19 mRNA vaccines could aid cancer development.”
- A leaked Pfizer indemnification agreement forces countries to put up sovereign assets, bank reserves, military bases, & embassy buildings as collateral for expected ‘vaccine’ injury lawsuits.
Does this sound like a company that should be trusted with anything?
How Could BioNTech Purchase a Factory for its Vaccine Before the Drug Was Approved?
One of the many important and untold stories of the COVID-19 response involves, not surprisingly, the German company BioNTech…
By Robert Kogon April 9, 2024
Article Excerpts:
As at least my readers will know, BioNTech is the actual developer, owner and legal manufacturer of what is more commonly and misleadingly known as the ‘Pfizer’ COVID-19 vaccine. It is also the authorisation holder for almost all markets, including the EU, the U.K. and the U.S. But circa 2020, the legal manufacturer of the drug had a big problem: having never previously brought any product to market, it did not have any manufacturing facilities.
The problem was solved by its purchase from Novartis of the somewhat infamous Behringwerke or ‘Behring Works’ in Marburg. Not only was the facility the site of the eponymous Marburg virus outbreak in 1967, but during the Second World War, as a subsidiary of the IG Farben chemical trust, it had been used to manufacture experimental vaccines for testing on concentration camp inmates at Buchenwald. This human experimentation was at the very heart of the Nuremberg ‘Doctors’ Trial’, as can be seen here. (See link for article)
______________
The author queries how BioNTech was able to complete acquisition and refitting of Behring Works in Marburg before the ‘vaccine’ was even approved. Did they know something we didn’t?
https://www.dossier.today/p/pfizer-to-pay-0-in-taxes-despite
Pfizer to pay $0 in taxes, despite billions in income
Every year, Pfizer sends an army of lobbyists to Washington, D.C., seeking to manipulate the tax code to their benefit.
- Go here for “Pfizer’s Tax Dodging Rx: Stash Profits Offshore”
- Go here to learn of the 2015 partnership Pfizer made with Israeli Bar Ilad University Research and Development Company Ltd. (BIRAD) managed by Prof. Ido Bachelet for programmable nanorobots that are injected into humans, issuing them an IP address and connecting them to the internet to be controlled remotely using magnetic fields. They can be directed to a specific part of the body and then activated with a push of a button.
- Bachelet admits a treatment in mammals must overcome the immune response triggered when a foreign object enters the body.
- It is also known that nanorobots are capable of molecular level destruction of the human body which could be used in bioterrorism to torture an opponent.
- There is also a privacy issue due to the lack of informed consent and ‘snooping’ for surveillance purposes, as well as the issue of who controls it (insiders vs outsiders) and the fact it can’t be seen.
- Nobody has a clue what this tech does to the environment.
- Go here for a map of nanotech global catastrophic risks.
- Go here to learn how the super computer CERN teamed up with cloud vendor Rackspace to build a “hybrid cloud” which uses a mix of servers and storage accessed all over the internet to handle an enormous amount of data. The question to ask here is what for? Here’s a few frightening ideas:
- Digital ID/health & ‘vaccine’ passport
- CBDC
- 15 minute cities, which is why electric cars are being pushed. A geogrid (think electric fence) will prohibit you from traveling outside your zone.
- 5G’s grid based, real-time imaging system that creates a living map of the world over time, recorded for playback purposes and which can be edited (sped up, slowed down, or deleted).
- ‘Smart’ buildings and cities that are dangerous to biological forms.
- Social credit system connected with social media and financial institutions for widespread censorship & ‘civic listening.’
- In short, 24/7 surveillance
- The simulation of nanostructured materials requires high performance computers and modern calculation methods. CERN makes this happen due to its ability to handle Big Data.
- Go here for specific examples of how Pharma and U.S. Government agencies are bedfellows.
Pfizer is part and parcel of this global end-game. Which should really make you question a Pfizer Lyme ‘vaccine.’
Patients question CDC about Pfizer Lyme vaccine–Part 2
By Lonnie Marcum
4/11/24
On March 6-7, 2024, I joined a group of other Lyme and tick-borne disease advocates meeting with members of the CDC and a representative from Pfizer in Atlanta.
Our goal was to develop a list of questions to help inform the Lyme vaccine program development and implementation if the Pfizer VLA15 Lyme vaccine (currently in phase 3 clinical trials) is approved for use in the U.S.
The advocates were invited in an effort to develop relationships that expand the CDC’s understanding of the lived experience of Lyme disease (from patients, caregivers and leadership from patient-driven research organizations).
From the beginning, I’ve aimed to be as transparent as possible with the Lyme community. As I shared in detail here, it was an extremely valuable meeting where the group brought forth scores of questions for Pfizer.
It has taken some time for the final list of questions to be compiled and reviewed by each of the participants. Below are the finalized questions as submitted to Pfizer today.
Setting the stage
This comprehensive list sets the stage for future communications with the CDC regarding any Lyme disease vaccines that may become available.
A special thanks goes out to Dr. Sue Visser of the CDC for coordinating the meeting and following through with all the details.
Also grateful to Dr. Lyle Petersen, Dr. Grace Marx and Dr. Paul Mead, CDC officials who stayed with us from start to finish. They listened to our personal stories and answered many technical questions.
From left: Lonnie Marcum, Olivia Goodreau, Bruce Fries, Holiday Goodreau, Wendy Adams, Bonnie Crater. Not shown: Pat Smith, who attended remotely.
And of course a HUGE shout-out to the other advocates in attendance: Wendy Adams, Bonnie Crater, Bruce Fries, Holiday Goodreau, Olivia Goodreau and Patricia Smith. (Click links to find out more about them.)
I sincerely hope we can get these questions answered. I will keep you informed as I learn more information from the CDC or Pfizer.
Questions for Pfizer
General Questions
- Why didn’t Pfizer engage the Lyme disease community sooner in the vaccine development process?
- Can you tell us why a presentation about VLA15 wasn’t provided by Pfizer for this meeting?
- Is there a way to have access to presentations previously given at scientific conferences (e.g., the Gordon Conference)?
- Would Pfizer be able to make a presentation about VLA15 and the results of the clinical trials at a meeting convened by CDC with a broad group of researchers and non-researchers from the Lyme community?
Questions About Vaccine Development
- Which OspA fragments were used in VLA15?
- Does the ST1-OspA that was used cover the strains in California?
- How was OspA modified to prevent autoimmune reactivity to HLA/LFA?
- What are the vaccine technology and ingredients? (Background note: there are concerns about the danger of those with alpha-gal receiving mammalian products via healthcare products.)
- Why was OspA chosen as the target, given the LYMERix® concerns?
- How is this vaccine similar and different than LYMERix®?
- Specifically, how have the vaccine’s developers edited out the putative mimic of hLFA-1? Is there any data to confirm that additional epitopes are not problematic, if the mimic of hLFA-1 is not the only one that caused an autoimmune reaction in LymeRix? What data convinced you that VLA15 would be safer than LYMERix®?
- Did Pfizer investigate any of the peer-reviewed articles on the problems that were thought to have affected those who took LYMERix® (for example, those related to HLA or demyelination)? If so, please provide a summary. If not, why?
- What happened to the Baxter Lyme disease vaccine? Did Pfizer look into this vaccine? Did Pfizer acquire any portion of the Baxter Lyme disease vaccine division?
- What happened to the Connaught ImmuLyme vaccine? Did Pfizer look into this vaccine?
- How does VLA15 prevent Lyme disease?
- How long does it take for human antibodies to develop after the OspA vaccine? How long does this response continue?
- How long does it take for the antibodies in the human blood to deactivate the Borrelia in the tick (minutes, hours, days)?
- What are the transmission assumptions used in the development of VLA15?
- Do you have plans for other tickborne disease vaccines (e.g., babesiosis, bartonella, relapsing fever species)?
- Do you keep a repository of trial samples for use in future research? If so, who can access them?
- What are the greatest challenges Pfizer has faced in developing this vaccine? What challenges do you anticipate facing in the future?
- Is there anything you can tell us that wasn’t in the press releases?
Questions About the VLA15 Trials
- On the April 2022 press release, can you please clarify whether the pediatric immunogenicity response was similar or different for 2 or 3 dose schedule?
- Who conducts Phase 4 studies? Does Pfizer intend to conduct Phase 4 studies?
- One of the press releases references “observer blind”. Is “observer blind” different from “double blind”?
- Can you please clarify the calculus of going from 6,000 target participants to the final recruited total of 9,437 participants?
- Were data from the 3,000 discontinued VALOR participants retained? If so, how will they be analyzed?
- Does the VLA15 series need to start at a specific time of year to optimize immunological response?
- On what data did Pfizer base the timing of a 12-month booster? If you will target boosters before “peak season” (as referenced in the 12/4/23 press release), how will “peak season” be defined?
- In the 2/4/22 press release, how was the “subset” of phase 2 participants selected for the booster study?
- How many of the 9,437 participants were enrolled from the US? Europe? Canada?
- How do we know that one booster is sufficient when the initial series required 3 vaccines?
- What were the participant incentives?
- Would you conduct subgroup analyses of those who contracted COVID-19 during the study?
- In the clinical trials, participants were either “Lyme naïve” or had “cleared past infection.” What diagnostic method was used to determine a person’s Lyme status? Did you test for other infections? What diagnostics were run overall, across time?
- What Lyme disease testing method is being used to verify vaccine efficacy?
- Do you have data on the safety and efficacy of this vaccine in people who are pregnant? Do you have data on people who became pregnant during the trial? If so, what did the data show?If there are resulting pregnancies, will those pregnancies be followed, and will any offspring born be followed over time especially for any Lyme cases (e.g., vaccine failures)? Will specimens be collected?
- Did you enroll people who were known to have non-Lyme tickborne diseases? If so, can you do subgroup analyses of them?
- Have you evaluated the safety and efficacy of VLA15 in immunocompromised patients? If not, will you? How did you define “immunocompromised”?
- Did you enroll people with non-communicable diseases that weren’t part of the exclusion criteria? Do you intend to do subgroup analyses of this population?
- What is the threshold to determine protection and how is this threshold determined? How long does protection last?
- How long after getting the 3rd dose does it take to be fully protected?
- Are you partially protected after one or two doses? If so, how much?
- How long are clinical trial participants being monitored? If so, how?
- Are there any sex-based differences in the immunological response?
- Is there any therapeutic value to VLA15?
- Can you provide the GCP guidelines that were violated by Care Access, leading to the removal of this contractor?
Questions About Adverse Events and Side Effects
- Can you assess the safety and efficacy of VLA15 in those who have tickborne diseases? Do you have plans to conduct subgroup analyses?
- What is the safety profile and what are the side effects of VLA15? What were the worst side effects?
- Do you have any plans to evaluate the safety and efficacy of VLA15 in patients with persistent Lyme disease?
- Can you get VLA15 if you’re sick (e.g., have cold symptoms, etc.)?
- Can this vaccine be co-administered with other vaccines? If not, what is the wait time?
- Is there a plan to co-administer the Lyme vaccine with the fall vaccines (e.g., COVID, flu, etc.) in order to optimize timing of efficacy?
Questions About Post-Licensure
- Are there future studies planned if VLA15 if licensed in the U.S, post-licensure (e.g., with those excluded from VALOR: pregnant people, breastfeeding people, elderly people)?
- Are there plans to expand clinical trials to other regions of the world?
- Where is/will VLA15 be manufactured?
- What will the cost be? Will it be covered by insurance? If so, under what circumstances?
- If recommendations from ACIP are restrictive to geography, will Pfizer conduct additional studies or trials to establish use in other geographic areas to support broader uptake?
- What are the logistics around vaccine implementation (shelf life, storage requirements, etc.)?
- Are there anticipated impacts of VLA15 on subsequent diagnostic testing for future infections (e.g., false positives for Lyme disease, etc.)?
- Will Pfizer enlist patient access programs to support uptake and accessibility to the vaccine?
Questions about Communications and Rollout
- When can the public have access to the marketing plan described in one of the VLA15 press releases?
- How will Pfizer ensure that the public understands the scope of protection from VLA15, and specifically that it will not protect the public from tickborne diseases other than Lyme disease?
Questions for CDC
General Questions
- Would Pfizer be able to convene a meeting at which the VLA clinical trial findings could be presented to the broad research and non-research Lyme community?
Questions About Adverse Events and Side Effects
- When a person reports to VAERS, is their report/symptom placed into a coding system (used by the FDA or others), or are their symptoms investigated and analyzed at face value? [VAERS stands for Vaccine Adverse Event Reporting System]
- What is the reporting and investigation process of VAERS?
- Do we currently (during the phase 3 clinical trial) have public access to adverse event data from the clinical trials (through VAERS or otherwise)? Does VAERS receive reports pre-licensure? If so, how are VAERS reports considered by FDA for licensure?]
Questions About Post-Licensure
- What can be shared publicly about the ACIP member vetting process?
- What is the conflict of interest process for vetting ACIP members?
- If a person is shown to have a conflict of interest, is there a process to remove them? Is this information disclosed?
Will VLA15 be considered for the Vaccines for Children program? - Would special populations get recommendations in the future, even if they were not included in the clinical trials?
- Do states have an independent role in determining if a vaccine is included in the Vaccines for Children program?
Questions about Communications and Rollout
- What are CDC’s plans for vaccine rollout, including website content?
- How will CDC incorporate information about vaccine safety monitoring systems in its vaccine rollout?
Questions for FDA
Questions About the VLA15 Trial
- Does FDA have a statement on why Pfizer discontinued a large number of participants in their US VALOR study?
- Why did FDA clear Care Access (contractor)?
- Why were FDA’s findings different than Pfizer’s?
- If VAERS receives reports pre-licensure, how are these reports considered by FDA for licensure?
Questions for Department of Defense (DoD)
Questions About Post-Licensure
- What is the vaccine recommendation process for DoD?
LymeSci is written by Lonnie Marcum, a physical therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on Twitter: @LonnieRhea Email her at: lmarcum@lymedisease.org.
______________
**Comment**
It’s quite obvious that Pfizer has a lot to hide. There are more questions presented than answers. The fact that Lyme advocates were handed press releases rather than real science should tell you everything you need to know. Pfizer would happily make us wait 75 years to get ‘vaccine’ data if they can get away with it.
It is clear Pfizer COVID shot data was falsified, their internal emails tried to cover up inconvenient fetal cell usage, the experimental gene therapy injections increase COVID and likely have negative efficacy, can cause an inflammatory syndrome, have utterly and hopelessly flopped, and are linked to more reports adverse reactions and death than any other vaccine in the history of VAERS, which only has a 1% capture rate.
Pfizer also quietly financed groups lobbying for ‘vaccine’ mandates and Pfizer colludes with the NIH through the Bayh-Dole Act and it’s NIH royalty-sharing agreement.
Are you seriously going to trust this company with a Lyme ‘vaccine?’
Go here for part 1.
Madison Area Lyme Support Group 